ClinicalTrials.gov
public full text
Public Domain
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine#1007112
- Facilitating Transition to Recommended PTSD Treatment#1164565
- EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking#865818
- Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)#1101643
- Effectiveness and moderators of PE and CPT in adult PTSD treatment: a systematic review and meta-analysis.#679710
Record · ID 911027
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive